Alvotech Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.05.25	Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm (GlobeNewswire)
19.05.25	Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today (GlobeNewswire)
16.05.25	Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm (GlobeNewswire)
16.05.25	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
13.05.25	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
09.05.25	Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada (GlobeNewswire)
09.05.25	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
08.05.25	Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm (GlobeNewswire)
07.05.25	Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update (GlobeNewswire)
07.05.25	Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 (GlobeNewswire)
06.05.25	Ausblick: Alvotech Registered präsentiert Quartalsergebnisse (finanzen.net)
05.05.25	Teva Pharma, Alvotech Announce FDA Approval For SELARSDI (RTTNews)
05.05.25	Teva, Alvotech Say FDA Approved Interchangeability For Stelara Biosimilar Across All Indications (RTTNews)
05.05.25	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) (GlobeNewswire)
02.05.25	Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) (GlobeNewswire)
22.04.25	Erste Schätzungen: Alvotech Registered legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
27.03.25	Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer (GlobeNewswire)
26.03.25	UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) (GlobeNewswire)
20.03.25	Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production (GlobeNewswire)
18.03.25	Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® (GlobeNewswire)
07.03.25	Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida (GlobeNewswire)
24.02.25	Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET (GlobeNewswire)
21.02.25	Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. (GlobeNewswire)
18.02.25	FDA To Review BLA For Alvotech's Proposed Biosimilar To Eylea - Quick Facts (RTTNews)
18.02.25	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) (GlobeNewswire)
27.01.25	Alvotech: FDA To Review BLA For AVT05 - Quick Facts (RTTNews)
27.01.25	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) (GlobeNewswire)
02.01.25	Alvotech Eyes Growth As Product Revenue Soars And New Launches Approach - Will The Stock Follow? (RTTNews)
23.12.24	Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 (GlobeNewswire)
13.11.24	Alvotech Reports Financial Results for the First Nine Months of 2024 (GlobeNewswire)
12.11.24	Ausblick: Alvotech Registered stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
07.11.24	Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 (GlobeNewswire)
04.11.24	European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) (GlobeNewswire)
30.10.24	Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET (GlobeNewswire)
29.10.24	Erste Schätzungen: Alvotech Registered veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
25.10.24	Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 (GlobeNewswire)
22.10.24	Alvotech And Teva Pharmaceuticals Announce Expansion Of SELARSDI's Indications (RTTNews)
22.10.24	Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (us (GlobeNewswire)
10.10.24	European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® (GlobeNewswire)
25.09.24	Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® (GlobeNewswire)
26.08.24	Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
15.08.24	Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 (GlobeNewswire)
15.08.24	European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) (GlobeNewswire)
01.08.24	Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET (GlobeNewswire)
22.07.24	STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe (GlobeNewswire)
11.07.24	Alvotech Announces Closing of Private Debt Financing (GlobeNewswire)
02.07.24	Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® (GlobeNewswire)
01.07.24	Alvotech Issues New Shares to Holders of Convertible Bonds (GlobeNewswire)
01.07.24	Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 (GlobeNewswire)
26.06.24	Alvotech Receives Conversion Notices for Majority of Convertible Bonds (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swiss Life Hldg	822.20	0.66 %	K V
Swisscom	566.50	-0.09 %	K V
Nestle	87.80	-0.17 %	K V
Lonza Grp	563.00	-0.21 %	K V
Novartis	93.01	-0.30 %	K V
Holcim	95.56	-1.20 %	K V
Swiss Re	146.00	-1.72 %	K V
Geberit	598.60	-2.32 %	K V
Sika	218.80	-2.37 %	K V
Sonova Hldg	274.70	-2.48 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Alvotech Registered Shs Aktie VALOR 119799137 / ISIN LU2458332611

Nachrichten zu Alvotech Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten